Progression-free survival as a surrogate endpoint for overall survival | OTT
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Progression-free survival and overall survival. Progression-free... | Download Scientific Diagram
Cancers | Free Full-Text | Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
Extrapolation from Progression Free Survival to Overall Survival in O…
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
![PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f33163534f9a85acc25579932597eab0cf9e71ff/7-Figure1-1.png "PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar")
PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar
A) Disease-free survival, (B) progression-free survival and (C)... | Download Scientific Diagram
Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival - IOS Press
Cancers | Free Full-Text | Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy
Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect
Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy | British Journal of Cancer
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Comparison of progression-free survival (A) or overall survival (B)... | Download Scientific Diagram
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
